Instrumento Inactivo

Otros idiomas Jupiter Neurosciences, Inc.

Acciones

Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL in Parkinson's Disease	27/02/23
Jupiter Neurosciences, Inc. Announces Appointment of New Chief Financial Officer	13/01/23
Jupiter Neurosciences, Inc. Appoints Saleem Elmasri as Chief Financial Officer	12/01/23
Jupiter Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	02/12/22
Jupiter Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting Use of JOTROL™	14/06/22
Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	18/05/22
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	26/04/22
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	26/04/22
Jupiter Neurosciences, Inc. Announces Broadening of IP Estate for its Unique Resveratrol Formulation, JOTROL	01/03/22
Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™	23/02/22
Jupiter Neurosciences to Issue 2.2 Million Units in IPO	27/01/22
Jupiter Neurosciences, Inc. has filed an IPO.	12/10/21
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	12/10/21
Jupiter Neurosciences, Inc. Announces New Corporate Offices	21/09/21

No hay resultados para esta búsqueda